Journal of The Korean Society of Inherited Metabolic disease (대한유전성대사질환학회지)

The Korea Society of Inherited Metabolic Disease (대한유전성대사질환학회)
권호 표지

A Case of Carbamoyl Phosphate Synthetase 1 Deficiency with Novel Mutations in CPS1 Treated by Liver Cell Transplantation

신생아기에 새로운 CPS1 유전자 돌연변이가 확인되고, 간세포이식 시행 받은 Carbamoyl phosphatase synthetase 1 deficiency 1례

  • Lee, Jisun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yang, Aram (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jinsup (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Hyung-Doo (Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Sanghoon (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Suk-Koo (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cho, Sung Yoon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jin, Dong-Kyu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 이지선 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 양아람 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 김진섭 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 박형두 (성균관대학교 의과대학 삼성서울병원 진단검사의학과) ;
  • 이상훈 (성균관대학교 의과대학 외과학교실) ;
  • 이석구 (성균관대학교 의과대학 외과학교실) ;
  • 조성윤 (성균관대학교 의과대학 삼성서울병원 소아청소년과) ;
  • 진동규 (성균관대학교 의과대학 삼성서울병원 소아청소년과)
  • Published : 2017.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is an autosomal recessive disorder of the urea cycle that causes hyperammonemia. Two forms of CPS1D are recognized: a lethal neonatal type and a less severe, delayed-onset type. Neonatal CPS1D cases often present their symptoms within the first days of life. Delayed-onset cases are predominantly adolescents or adults, and infantile delayed-onset cases are rare. Severe hyperammonemia in the neonatal period leads to serious brain damage, coma, and death if not treated promptly. Therefore, early diagnosis and acute treatment are crucial. Despite the improvement of treatments, including continuous hemodialysis, ammonia-lowering agents, and a low-protein diet, the overall outcome of severe forms of hyperammonemia often remains disappointing. As the liver is the only organ in which ammonia is converted into urea, liver transplantation has been considered as an elegant and radical alternative therapy to classical dietary and medical therapies. However, liver transplantation has many disadvantages, such as a considerable risk for technical complications and perioperative metabolic derangement, especially in neonates. Additionally, there is a lack of suitable donor organs in most countries. According to recent studies, liver cell transplantation is a therapeutic option and serves as a bridge to liver transplantation. Here, we report a Korean CPS1D patient with novel mutations in CPS1 who was treated by liver cell transplantation after being diagnosed in the neonatal period and showed a good neurodevelopmental outcome at the last follow-up at six months of age.

Carbamoyl phosphate synthetase 1 (CPS1) 결핍은 요소회로 이상 질환 중 하나로 상염색체 열성으로 유전되며 2q35 염색체에 존재하는 CPS1 유전자 변이로 발생된다. CPS1의 완전한 결핍을 가진 경우 신생아 시기에 빠르게 진행하는 고암모니아혈증으로 발현한다. 신생아 시기의 심한 고암모니아혈증은 즉각적인 치료를 받지 않을 시 심각한 뇌 손상, 혼수, 사망에 이르기에 진단 시 응급 투석과 체계적인 집중 치료가 필요하다. 본 증례는 생후 4일 째 신생아실에서 발열, 경련, 고암모니아혈증이 확인되어 생화학적, 분자유전학적 방법으로 두 개의 새로운 변이 c.1117G>C (p.Ala373 Pro)와 c.1883G>T (p.Gly628Val)가 이형접합체로 발견되고 CPS1 결핍이 진단된 신생아에서 응급 투석 및 집중치료와 함께 궁극적인 치료인 간이식 전 간세포이식술을 생후 1개월에 시행하여 반복적인 고암모니아혈증 발생을 막고 불가역적인 신경손상을 예방하여 현재 생후 6개월까지 단기간 경과관찰 결과 성장과 발달 및 신경학적 예후가 좋음을 보고하는 바이다.

Keywords

References

  1. Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110:179-80. https://doi.org/10.1016/j.ymgme.2013.07.008
  2. Funghini S, Thusberg J, Spada M, Gasperini S, Parini R, Ventura L, et al. Carbamoyl phosphate synthetase 1 deficiency in Italy: clinical and genetic findings in a heterogeneous cohort. Gene 2012;493:228-34. https://doi.org/10.1016/j.gene.2011.11.052
  3. Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, Matsuo M, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis 2012;35:777-85. https://doi.org/10.1007/s10545-011-9427-0
  4. Ah Mew N, Lanpher BC, Gropman A, Chapman KA, Simpson KL, Urea Cycle Disorders Consortium, et al. Urea cycle disorders overview. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle, 1993.
  5. Kim KM, Lee S, Lee YJ, Park KM, Kim SC, Chun HB, et al. Living Related Donor Liver Transplantation in Children : Indication and Clinical Outcome. Korean J Pediatr 1998;41:622-32.
  6. Meyburg J, Das AM, Hoerster F, Lindner M, Kriegbaum H, Engelmann G, et al. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009;87:636-41. https://doi.org/10.1097/TP.0b013e318199936a
  7. Kwon CHD, Lee SK. Hepatocyte Transplantation. J Korean Soc Transplant 2009;23:1-7.
  8. Haberle J, Shchelochkov OA, Wang J, Katsonis P, Hall L, Reiss S, et al. Molecular defects in human carbamoy phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. Hum Mutat 2011;32:579-89. https://doi.org/10.1002/humu.21406
  9. Choon Hyuck David Kwon MDaS-KL, M.D. Hepatocyte Transplantation. J Korean Soc Transplant 2009;23:1-7.
  10. Bachmann C. Long-term outcome of patients with urea cycle disorders and the question of neonatal screening. Eur J Pediatr 2003;162 Suppl 1:S29-33. https://doi.org/10.1007/s00431-003-1347-z
  11. Haberle J, Shchelochkov OA, Wang J, Katsonis P, Hall L, Reiss S, et al. Molecular defects in human carbamoy phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. Hum Mutat 2011;32:579-89. https://doi.org/10.1002/humu.21406
  12. Choi R, Park HD, Yang M, Ki CS, Lee SY, Kim JW, et al. Novel Pathogenic Variant (c.580C>T) in the CPS1 Gene in a Newborn With Carbamoyl Phosphate Synthetase 1 Deficiency Identified by Whole Exome Sequencing. Ann Lab Med 2017;37:58-62. https://doi.org/10.3343/alm.2017.37.1.58
  13. Suh SH, Kim YM, Byun SY, Son SK, Kim SH, Kim HT, et al. A Case of Lethal Neonatal Type Carbamoyl Phosphate Synthetase 1 Deficiency with Novel Mutation of CPS1. J Korean Soc Inher Metab Dis 2016;16:109-14.
  14. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008;97:1420-5. https://doi.org/10.1111/j.1651-2227.2008.00952.x
  15. Jorns C, Ellis EC, Nowak G, Fischler B, Nemeth A, Strom SC, et al. Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med 2012;272:201-23. https://doi.org/10.1111/j.1365-2796.2012.02574.x
  16. Sokal EM. Treating inborn errors of liver metabolism with stem cells: current clinical development. J Inherit Metab Dis 2014;37:535-9. https://doi.org/10.1007/s10545-014-9691-x